Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non–Small-Cell Lung Cancer
Gastric cancer and lung cancer impose a substantial burden on patients. In light of the high mortality rate and quality-of-life issues associated with these 2 types of cancer, there is a marked need for additional therapeutic options to improve outcomes for patients with gastric or lung cancer.
Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treament of Patients with Genotype 1 Chronic Hepatitis C Infection
Hepatitis C virus (HCV) infection is the most common blood-borne disease; approximately 3.2 million Americans and 130 million to 170 million individuals worldwide are infected with HCV. Chronic HCV infection has been called a silent epidemic; the disease can remain quiescent for decades before clinically significant symptoms appear. Because many Americans who are currently living with HCV were infected before blood screening testing for HCV was performed, the prevalence of HCV complications is likely to rise as these individuals enter their 50s and 60s.
Imbruvica (Ibrutinib), First-in-Class Bruton’s Tyrosine Kinase Inhibitor, Receives Expanded Indications for Patients with Relapsed Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL), the most common type of leukemia in adults, is a cancer of B-cell lymphocytes, which originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing an immune response. In CLL, excess B-cells accumulate in the bone marrow and blood, where they crowd out healthy blood cells.
Invokamet (Canagliflozin plus Metformin HCl): First Fixed-Dose Combination with an SGLT2 Inhibitor Approved for the Treatment of Patients with Type 2 Diabetes
Diabetes is a chronic disease that affects an estimated 29.1 million individuals in the United States—approximately 9.3% of the US population. In addition, a staggering 37% of US adults have prediabetes, placing them at a high risk for diabetes. Coinciding with the aging of the US population, the prevalence of diabetes is projected to increase dramatically over the next few decades, from approximately 1 in 10 adults today to approximately 1 in 3 adults by 2050. Approximately 90% to 95% of all cases of diabetes are type 2 diabetes mellitus, a disease that is characterized by insulin resistance and a gradual decline in the ability of the pancreas to produce insulin.
Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera
Similar to myelofibrosis and essential thrombocythemia, polycythemia vera is a Philadelphia chromosome–negative myeloproliferative neoplasm. Polycythemia vera is characterized by the clonal stem-cell proliferation of red blood cells, white blood cells, and platelets. Increased red blood cell mass results in the hyperviscosity of the blood, an increased risk for thrombosis, poor quality of life, and a shortened life expectancy.
Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 Diabetes
Diabetes is on the rise at an alarming rate in the United States. An estimated 9.3% of the US population, or 29.1 million people, are affected by diabetes. Furthermore, approximately 37% of all US adults (51% of people aged ≥65 years) have prediabetes, a condition that greatly increases their risk for developing diabetes. The prevalence of diabetes is projected to increase from 1 in 10 adults today to 1 in 3 adults by 2050, based on current trends and the aging of the population over the next few decades. Type 2 diabetes mellitus, a type of diabetes characterized by insulin resistance and the gradual decline in the ability of the pancreas to produce insulin, accounts for an estimated 90% to 95% of all cases of diabetes.
Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma
Melanoma, although not the most common skin cancer in the United States, is the most deadly. Based on data collected between 2004 and 2010, the 5-year survival rate for Americans with metastatic melanoma remains very low—only 16%—for all ages and races, and both sexes. The National Cancer Institute has estimated that 21.3 in 100,000 people will be diagnosed with melanoma of the skin in the United States in 2014. More than 9700 patients are estimated to die from melanoma in the same time frame.
Ofev (Nintedanib): First Tyrosine Kinase Inhibitor Approved for the Treatment of Patients with Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis, a debilitating lung disease, affects approximately 128,100 patients in the United States, with 48,000 new cases diagnosed annually. Idiopathic pulmonary fibrosis is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults (ie, aged 50-75 years). The disease is characterized by progressive worsening of dyspnea (shortness of breath) and lung function, as well as a poor prognosis. In fact, the median survival for patients with idiopathic pulmonary fibrosis in the United States is 2.5 to 3.5 years after diagnosis, with the disease claiming an estimated 40,000 lives annually.
Otezla (Apremilast), an Oral PDE-4 Inhibitor, Receives FDA Approval for the Treatment of Patients with Active Psoriatic Arthritis and Plaque Psoriasis
Psoriatic arthritis and psoriasis, often referred to as psoriatic diseases, are autoimmune diseases characterized by chronic inflammation, tissue and organ involvement, and the accelerated growth cycle of skin cells. Both psoriatic arthritis and psoriasis impose a substantial physical, emotional, and economic burden on the millions of individuals in the United States who are affected by these conditions.
Sivextro (Tedizolid Phosphate) Approved for the Treatment of Adults with Acute Bacterial Skin and Skin- Structure Infections
An acute bacterial skin and skin-structure infection (ABSSSI) is a bacterial infection of the skin with a lesion size of ≥75 cm2, which is measured by the area of redness, edema, or induration. The types of infections that comprise ABSSSIs include cellulitis or erysipelas, major cutaneous abscesses, and wound infections; these infections can be life-threatening and may require hospitalization and surgery.
Page 5 of 7
Results 41 - 50 of 69
Results 41 - 50 of 69